Entry into a Material Definitive Agreement Amendment to Merger and Share Exchange Agreement As previously disclosed, Impact BioMedical Inc., a Nevada corporation (the “Company” or “Impact”), is party to that certain Merger and Share Exchange Agreement, dated June 21, 2025 (the “Original Merger and Share Exchange Agreement”), by and among Dr Ashleys Limited, a Cayman Islands exempted company limited by shares (“PubCo”), Impact, Dr Ashleys Nevada Sub, Inc., a Nevada corporation and wholly owned…

Entry Into a Material Definitive Agreement. Debt Conversion Agreement On July 21, 2025, Impact BioMedical Inc. (the “Company” or “Borrower”) entered into a Debt Conversion Agreement with DSS, Inc. (“DSS” or “Lender”), pursuant to that certain loan made on March 31, 2023, by the Lender in the form of a revolving promissory note in the original amount of $12,000,000 (the “Original Note”), which was amended on January 18, 2024 to (i) extend the maturity date of the Loan to September 30, 2023, (i…

Entry Into a Material Definitive Agreement. On June 21, 2025, Impact BioMedical Inc. (“Impact”), Dr Ashleys Limited, a Cayman Islands exempted company limited by shares (“PubCo”), Dr Ashleys Nevada Sub, Inc., a Nevada corporation and wholly-owned subsidiary of PubCo (“Merger Sub”), Dr Ashleys Bio Labs Limited, a Cayman Islands exempted company limited by shares (“Dr Ashleys Cayman”), and Kanans Visvanats (a.k.a. Kannan Vishwanatth), a Latvian national, solely in his capacity as the sole share…

Entry Into a Material Definitive Agreement. Debt Conversion Agreement As previously reported on the Company’s current report on Form 8-K, filed March 28, 2025 (the “Initial 8-K”), Impact BioMedical Inc. (the “Company”) entered into a Debt Conversion Agreement (the “Debt Conversion Agreement”), dated March 24, 2025, with DSS, Inc. (“DSS”), pursuant to that certain Amended and Restated Promissory Note, dated September 16, 2024 (the “Promissory Note”). The original principal amount of the Promis…

Entry Into a Material Definitive Agreement. Debt Conversion Agreement As previously reported, Impact BioMedical Inc. (the “Company”) entered into a Debt Conversion Agreement, dated March 24, 2025, with DSS, Inc., pursuant to that certain Amended and Restated Promissory Note, dated September 16, 2024 (the “Promissory Note”). The original principal amount of the Promissory Note was $12,000,000, and as of March 24, 2025, the Promissory Note had a principal balance of $13,176,477.03. In connectio…

Director — Mr. Chan Heng Fai Ambrose: The appointment of a highly experienced director with extensive industry background.

Chief Executive Officer — Frank D. Heuszel: The CEO entered into a new employment agreement with the company, outlining his compensation and terms of employment.

Entry Into a Material Definitive Agreement. On September 16, 2024, Impact Biomedical Inc., (the “Company”), entered into an underwriting agreement (the “Underwriting Agreement”) with Revere Securities, LLC., as representative (the “Representative”) of the underwriters named therein (the “Underwriters”), pursuant to which the Company agreed to sell to the Underwriters in a firm commitment initial public offering (the “Offering”) an aggregate of 1,500,000 of the Company’s shares of common stock…

Director — Heng Fai Ambrose Chan: Mr. Chan resigned as a member of the Board of Directors, and Mr. Grady was appointed to replace him.

Entry Into a Material Definitive Agreement. Effective January 18, 2024, DSS, Inc., a New York corporation (“DSS”) and Impact BioMedical, Inc., a Nevada corporation (“Impact”) entered into an amendment to the revolving promissory note dated March 1, 2023 (the “Original Note”), whereby DSS loaned Impact an original amount of up to $12,000,000 (the “Loan”). Pursuant to the amendment, DSS agreed to amend the existing Original Note to (1) extend the maturity date of the Loan to September 30, 2030,…

Entry Into a Material Definitive Agreement. Exchange Agreement Effective October 31, 2023, Impact BioMedical, Inc. (the “Company”), entered into a Share Exchange Agreement (the “Exchange Agreement”) with DSS BioHealth Security, Inc. (“DBH”), pursuant to which, DBH agreed to exchange 60,496,091 shares of the Company’s common stock for 60,496,091 shares of Series A Convertible Preferred Stock (the “Series A Stock”, and such transaction, the “Exchange”). The Exchange was consummated on October 3…

Material Modifications to Rights of Security Holders. To the extent required by this Item 3.03, the information contained in